Tanshinone in Polycystic Ovary Syndrome

Launched by HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE · Oct 12, 2011

Keywords

ClinConnect Summary

No description provided

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Presence of PCOS diagnosed based on the Androgen Excess Society criteria. All subjects must have hyperandrogenism (hirsutism and/or hyperandrogenemia), ovarian dysfunction (oligoanovulation and/or polycystic ovaries), and exclusion of other androgen excess related disorders. Oligomenorrhea is defined as an intermenstrual interval \>35 days or \<8 menstrual bleedings in the past year. Amenorrhea is defined as an intermenstrual interval \>90 days. Clinical hyperandrogenism is defined as a Ferriman-Gallwey (FG) score ≥5
• • Age of women from 18 to 35 years；
• • No desire of children within 6 month and use condoms for contraception.
• Exclusion Criteria:
• • Use of hormonal drugs or other medications, which can affect the results of the study especially Chinese herbal prescriptions in the past 12 weeks；
• • Patients with other androgen excess endocrine disorders including 21-hydroxylase deficiency, hyperprolactinemia, Cushing syndrome, severe insulin resistance, thyroid dysfunction；
• • Patients with history of sever cardiac , pulmonary, hepatic, renal, neurologic disease or mental illness；
• • Pregnancy or lactation.